Efficacy, safety, tolerability, and PK of the HDAC inhibitor resminostat in sorafenib-refractory hepatocellular carcinoma (HCC): Phase II SHELTER study.

被引：0
|
作者：
Bitzer, Michael
Horger, Marius
Ganten, Tom M.
Lauer, Ulrich M.
Woerns, Marcus A.
Siveke, Jens T.
Dollinger, Matthias M.
Gerken, Guido
Wege, Henning
Giannini, Edoardo G.
Zagonel, Vittorina
Cillo, Umberto
Trevisani, Franco
Santoro, Armando
Montesarchio, Vincenzo
Hauns, Bernhard
Asche, Julia
Jankowsky, Ruediger
Mais, Anna
Hentsch, Bernd
机构：
[1] Univ Tubingen, Med Univ Clin, Tubingen, Germany
[2] Univ Tubingen, Tubingen, Germany
[3] Heidelberg Univ, Dept Internal Med, Heidelberg, Germany
[4] Med Univ Clin, Mainz, Germany
[5] Tech Univ Munich, Dept Internal Med 2, D-80290 Munich, Germany
[6] Univ Halle Wittenberg, Dept Internal Med, D-06108 Halle, Germany
[7] Univ Duisburg Essen, Dept Gastroenterol & Hepatol, Essen, Germany
[8] Univ Hosp Hamburg Eppendorf, Hamburg, Germany
[9] Univ Genoa, Dept Internal Med, Gastroenterol Unit, I-16126 Genoa, Italy
[10] Ist Oncol Veneto IRCCS, Padua, Italy
[11] Azienda Univ Padova, Hepatobiliary Surg & Liver Transplant Unit, Padua, Italy
[12] Univ Bologna, Bologna, Italy
[13] Humanitas Canc Ctr, Dept Oncol, Rozzano, Italy
[14] UO Oncol Osped Cotugno Napoli, Naples, Italy
[15] 4SC AG, Planegg Martinsried, Germany
[16] 4SC AG, Martinsried, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4115
引用
收藏
页数：1
相关论文
共 50 条
  • [41] EFFICIENT HDAC INHIBITION AND TARC REDUCTION IN PATIENTS WITH REFRACTORY HODGKIN LYMPHOMA TREATED WITH RESMINOSTAT - PK/PD DATA FROM THE PHASE II SAPHIRE STUDY
    Walewski, J.
    Henning, W.
    Borsaru, G.
    Moicean, A.
    Hellmann, A.
    Janikova, A.
    Hauns, B.
    Mais, A.
    Ammendola, A.
    Herz, T.
    Kohlhof, H.
    Hentsch, B.
    HAEMATOLOGICA, 2012, 97 : 83 - 83
  • [42] Phase Ib dose-escalation study of a phase II randomized trial to assess the safety and tolerability of tigatuzumab (CS-1008) in combination with sorafenib in patients (pts) with advanced hepatocellular carcinoma (HCC)
    Cheng, Ann-Lii
    Kang, Yoon-Koo
    Ryoo, Baek-Yeol
    Yen, Chia-Jui
    Lim, Ho Yeong
    Oh, Do-Youn
    Austin, TaShara
    Wang, Qiang
    Greenberg, Jonathan
    Beckman, Robert A.
    Kudo, Masatoshi
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [43] Phase I/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): Phase I safety and efficacy analyses.
    Kelley, Robin Kate
    Abou-Alfa, Ghassan K.
    Bendel, Johanna C.
    Kim, Tae -You
    Borad, Mitesh J.
    Yong, Wei-Peng
    Morse, Michael
    Kang, Yoon-Koo
    Rebelatto, Marlon
    Makowsky, Mallory
    Xiao, Feng
    Morris, Shannon R.
    Sangro, Bruno
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [44] Phase II study of first-line trebananib plus sorafenib in patients with advanced hepatocellular carcinoma (HCC)
    Abou-Alfa, Ghassan K.
    Blanc, Jean-Frederic
    Miles, Steven
    Ganten, Tom M.
    Trojan, Jorg
    Cebon, Jonathan S.
    Liem, Andre K. D.
    Lipton, Lara Rachel
    Gupta, Charu
    Wu, Benjamin
    Litten, Jason B.
    Saltz, Leonard
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [45] A phase II study of sorafenib in combination with tegafur/uracil (UFT) for Asian patients with advanced hepatocellular carcinoma (HCC)
    Shen, Y.
    Hsu, C.
    Hsu, C.
    Lin, Z.
    Chen, P.
    Shao, Y.
    Huang, T.
    Ding, Y.
    Cheng, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [46] Continuous-dose regorafenib (REG) in hepatocellular carcinoma (HCC): Phase I safety and pharmacokinetic (PK) study
    Finn, Richard S.
    Blumenschein, George R.
    Tolcher, Anthony W.
    Leong, Stephen
    Boix, Oliver
    Diefenbach, Konstanze
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [47] Phase Ib/II study of sorafenib (SOR) and pembrolizumab (PEM) in patients (pts) with advanced hepatocellular carcinoma (HCC)
    Iyer, Renuka
    Sonti, Sahithi
    Mahalingam, Devalingam
    Mukherjee, Sarbajit
    Chakraborty, Sayan
    Attwood, Kristopher
    George, Anthony
    Maguire, Orla
    Minderman, Hans
    Fountzilas, Christos
    CANCER RESEARCH, 2024, 84 (07)
  • [48] Phase II study of efficacy of bevacizumab and erlotinib in inoperable previously untreated hepatocellular carcinoma (HCC)
    Govindarajan, R.
    Siegel, E.
    Makhoul, I.
    Williamson, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [49] Updated efficacy and safety of KEYNOTE-224: A phase II study of pembrolizumab (pembro) in patients with advanced hepatocellular carcinoma (HCC)
    Kudo, Masatoshi
    Finn, Richard S.
    Edeline, Julien
    Cattan, Stephane
    Ogasawara, Sadahisa
    Palmer, Daniel H.
    Verslype, Chris
    Zagonel, Vittorina
    Fartoux, Laetitia
    Vogel, Arndt
    Sarker, Debashis
    Verset, Gontran
    Chan, Stephen Lam
    Knox, Jennifer J.
    Daniele, Bruno
    Gurary, Ellen B.
    Siegel, Abby B.
    Jain, Lokesh
    Cheng, Ann-Lii
    Zhu, Andrew X.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [50] Efficacy and safety of TACE combined with anlotinib compared with TACE alone among patients with intermediate or advanced hepatocellular carcinoma (HCC): A randomized, controlled, phase II clinical study.
    Zeng, Hui
    Shao, Guoliang
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 581 - 581
12345